# SENATE, No. 791 STATE OF NEW JERSEY 220th LEGISLATURE

INTRODUCED JANUARY 18, 2022

Sponsored by: Senator TROY SINGLETON District 7 (Burlington)

#### **SYNOPSIS**

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

#### **CURRENT VERSION OF TEXT**

As introduced.



2

1 AN ACT concerning health insurance coverage for prostate cancer 2 screening and amending P.L.1996, c.125 and supplementing 3 various parts of the statutory law. 4 5 **BE IT ENACTED** by the Senate and General Assembly of the State 6 of New Jersey: 7 8 1. Section 1 of P.L.1996, c.125 (C.17:48E-35.13) is amended 9 to read as follows:. 10 1. <u>a.</u> No health service corporation contract providing hospital or medical expense benefits [for groups with greater than 49 11 persons] shall be delivered, issued, executed or renewed in this 12 13 State, or approved for issuance or renewal in this State by the 14 Commissioner of Insurance on or after the effective date of [this act] P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract 15 16 provides benefits to any named subscriber or other person covered 17 thereunder for expenses incurred in conducting an annual 18 [medically recognized diagnostic examination including, but not 19 limited to, a digital rectal examination and a prostate-specific 20 antigen test for men age 50 and over who are asymptomatic and for 21 men age 40 and over with a family history of prostate cancer or other prostate cancer risk factors ] prostate cancer screening. 22 23 The benefits shall be provided to the same extent as for any other 24 medical condition under the contract except that no deductible, 25 coinsurance, copayment, or any other cost-sharing requirement on 26 the benefits shall be imposed. 27 This section shall apply to all health service corporation 28 contracts in which the health service corporation has reserved the 29 right to change the premium. 30 b. As used in this section: "Prostate cancer screening" means medically viable methods for 31 32 the detection and diagnosis of prostate cancer, which includes a 33 digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also 34 35 include subsequent follow up testing as direct by a health care 36 provider, including, but not limited to: 37 (1) urinary analysis; 38 (2) serum biomarkers; (3) medical imaging, including, but not limited to, magnetic 39 40 resonance imaging. 41 (cf: P.L.1996, c.125, s.1) 42 43 2. Section 2 of P.L.1996, c.125 (C.17:48-6p) is amended to 44 read as follows:

**EXPLANATION** – Matter enclosed in **bold-faced brackets** [thus] in the above bill is not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

1 2. No hospital service corporation contract providing hospital or 2 medical expense benefits [for groups with greater than 49 persons] 3 shall be delivered, issued, executed or renewed in this State, or 4 approved for issuance or renewal in this State by the Commissioner 5 of Insurance on or after the effective date of [this act] P.L.1996, 6 c.125 (C.17:48E-35.13 et al.), unless the contract provides benefits 7 to any named subscriber or other person covered thereunder for 8 expenses incurred in conducting an annual [medically recognized 9 diagnostic examination including, but not limited to, a digital rectal 10 examination and a prostate-specific antigen test for men age 50 and 11 over who are asymptomatic and for men age 40 and over with a 12 family history of prostate cancer or other prostate cancer risk 13 factors] prostate cancer screening. 14 The benefits shall be provided to the same extent as for any other 15 medical condition under the contract except that no deductible, 16 coinsurance, copayment, or any other cost-sharing requirement on 17 the benefits shall be imposed. 18 This section shall apply to all hospital service corporation 19 contracts in which the hospital service corporation has reserved the 20 right to change the premium. 21 b. As used in this section: 22 "Prostate cancer screening" means medically viable methods for 23 the detection and diagnosis of prostate cancer, which includes a 24 digital rectal exam and the prostate-specific antigen test and 25 associated laboratory work. "Prostate cancer screening" shall also 26 include subsequent follow up testing as direct by a health care 27 provider, including, but not limited to: (1) urinary analysis; 28 29 (2) serum biomarkers; 30 (3) medical imaging, including, but not limited to, magnetic 31 resonance imaging. 32 (cf: P.L.1996, c.125, s.2) 33 34 3. Section 3 of P.L.1996, c.125 (C.17:48A-7n) is amended to 35 read as follows: 36 3. No medical service corporation contract providing hospital or 37 medical expense benefits [for groups with greater than 49 persons] 38 shall be delivered, issued, executed or renewed in this State, or 39 approved for issuance or renewal in this State by the Commissioner 40 of Insurance on or after the effective date of [this act] P.L.1996, 41 c.125 (C.17:48E-35.13 et al.), unless the contract provides benefits 42 to any named subscriber or other person covered thereunder for 43 expenses incurred in conducting an annual [medically recognized 44 diagnostic examination including, but not limited to, a digital rectal 45 examination and a prostate-specific anitgen test for men age 50 and 46 over who are asymptomatic and for men age 40 and over with a

1 family history of prostate cancer or other prostate cancer risk 2 factors prostate cancer screening. 3 The benefits shall be provided to the same extent as for any other 4 medical condition under the contract except that no deductible, 5 coinsurance, copayment, or any other cost-sharing requirement on the benefits shall be imposed. 6 7 This section shall apply to all medical service corporation 8 contracts in which the medical service corporation has reserved the 9 right to change the premium. 10 b. As used in this section: "Prostate cancer screening" means medically viable methods for 11 the detection and diagnosis of prostate cancer, which includes a 12 13 digital rectal exam and the prostate-specific antigen test and 14 associated laboratory work. "Prostate cancer screening" shall also 15 include subsequent follow up testing as direct by a health care 16 provider, including, but not limited to: 17 (1) urinary analysis; 18 (2) serum biomarkers; 19 (3) medical imaging, including, but not limited to, magnetic 20 resonance imaging. 21 (cf: P.L.1996, c.125, s.3) 22 23 4. Section 4 of P.L.1996, c.125 (C.17B:27-46.10) is amended 24 to read as follows: 25 4. No group health insurance policy providing hospital or medical expense benefits [for groups with greater than 49 persons] 26 27 shall be delivered, issued, executed or renewed in this State, or 28 approved for issuance or renewal in this State by the Commissioner 29 of Insurance on or after the effective date of [this act] P.L.1996, 30 c.125 (C.17:48E-35.13 et al.), unless the policy provides benefits to 31 any named insured or other person covered thereunder for expenses incurred in conducting an annual [medically recognized diagnostic 32 33 examination including, but not limited to, a digital rectal 34 examination and a prostate-specific antigen test for men age 50 and 35 over who are asymptomatic and for men age 40 and over with a 36 family history of prostate cancer or other prostate cancer risk 37 factors] prostate cancer screening. 38 The benefits shall be provided to the same extent as for any other 39 medical condition under the policy except that no deductible, 40 coinsurance, copayment, or any other cost-sharing requirement on 41 the benefits shall be imposed. 42 This section shall apply to all group health insurance policies in 43 which the health insurer has reserved the right to change the 44 premium. 45 b. As used in this section: 46 "Prostate cancer screening" means medically viable methods for 47 the detection and diagnosis of prostate cancer, which includes a 48 digital rectal exam and the prostate-specific antigen test and

#### **S791** SINGLETON

5

1 associated laboratory work. "Prostate cancer screening" shall also 2 include subsequent follow up testing as direct by a health care 3 provider, including, but not limited to: 4 (1) urinary analysis; 5 (2) serum biomarkers; 6 (3) medical imaging, including, but not limited to, magnetic 7 resonance imaging. 8 (cf: P.L.1996, c.125, s.4) 9 10 5. Section 5 of P.L.1996, c.125 (C.26:2J-4.13) is amended to 11 read as follows: 12 5. A certificate of authority to establish and operate a health maintenance organization in this State shall not be issued or 13 continued by the Commissioner of Health on or after the effective 14 15 date of [this act] P.L.1996, c.125 (C.17:48E-35.13 et al.) unless the 16 health maintenance organization provides health care services to 17 any enrollee which include an annual [medically recognized 18 diagnostic examination including, but not limited to, a digital rectal 19 examination and a prostate-specific antigen test for men age 50 and 20 over who are asymptomatic and for men age 40 and over with a 21 family history of prostate cancer or other prostate cancer risk 22 factors] prostate cancer screening. 23 The health care services shall be provided to the same extent as 24 for any other medical condition under the contract except that no 25 deductible, coinsurance, copayment, or any other cost-sharing 26 requirement on the services shall be imposed. 27 The provisions of this section shall apply to all contracts for 28 health care services by health maintenance organizations under 29 which the right to change the schedule of charges for enrollee 30 coverage is reserved. b. As used in this section: 31 32 "Prostate cancer screening" means medically viable methods for 33 the detection and diagnosis of prostate cancer, which includes a 34 digital rectal exam and the prostate-specific antigen test and 35 associated laboratory work. "Prostate cancer screening" shall also 36 include subsequent follow up testing as directed by a health care 37 provider, including, but not limited to: 38 (1) urinary analysis; 39 (2) serum biomarkers; 40 (3) medical imaging, including, but not limited to, magnetic 41 resonance imaging. (cf: P.L.1996, c.125, s.5) 42 43 44 6. (New section) a. (1) Every individual health insurance 45 policy that provides hospital or medical expense benefits and is 46 delivered, issued, executed or renewed in this State pursuant to 47 chapter 26 of Title 17B of the New Jersey Statutes, or approved for 48 issuance or renewal in this State by the Commissioner of Banking

1 and Insurance, on or after the effective date of this act shall provide 2 coverage for an annual prostate cancer screening. 3 The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, 4 5 coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed. 6 7 The provisions of this section shall apply to all policies in which 8 the insurer has reserved the right to change the premium. b. As used in this section: 9 10 "Prostate cancer screening" means medically viable methods for 11 the detection and diagnosis of prostate cancer, which includes a 12 digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also 13 14 include subsequent follow up testing as direct by a health care 15 provider, including, but not limited to: 16 (1) urinary analysis; 17 (2) serum biomarkers; (3) medical imaging, including, but not limited to, magnetic 18 19 resonance imaging. 20 21 7. (New section) a. (1) Every individual health benefits plan 22 that provides hospital or medical expense benefits and is delivered, 23 issued, executed or renewed in this State pursuant to P.L.1992, 24 c.161 (C.17B:27A-2 et seq.) or approved for issuance or renewal in 25 this State on or after the effective date of this act shall provide 26 benefits for an annual prostate cancer screening. 27 The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, 28 29 coinsurance, copayment, or any other cost-sharing requirement on 30 the services shall be imposed. 31 The provisions of this section shall apply to all health benefits plans in which the carrier has reserved the right to change the 32 33 premium. 34 b. As used in this section: 35 "Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a 36 37 digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also 38 39 include subsequent follow up testing as direct by a health care 40 provider, including, but not limited to: 41 (1) urinary analysis; 42 (2) serum biomarkers; 43 (3) medical imaging, including, but not limited to, magnetic 44 resonance imaging. 45 46 8. (New section) a. Every small employer health benefits plan that provides hospital or medical expense benefits and is delivered, 47 48 issued, executed or renewed in this State pursuant to P.L.1992,

c.162 (C.17B:27A-17 et seq.) or approved for issuance or renewal
 in this State on or after the effective date of this act shall provide
 benefits for an annual prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.

8 The provisions of this section shall apply to all health benefits 9 plans in which the carrier has reserved the right to change the 10 premium.

11 b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a physician, including, but not limited to:

18 (1) urinary analysis;

(2) serum biomarkers;

20 (3) medical imaging, including, but not limited to, magnetic21 resonance imaging.

22

19

9. (New section) a. The State Health Benefits Commission
shall ensure that every contract purchased by the commission on or
after the effective date of this act that provides hospital or medical
expense benefits shall provide coverage for an annual prostate
cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.

32 b. As used in this section:

33 "Prostate cancer screening" means medically viable methods for 34 the detection and diagnosis of prostate cancer, which includes a 35 digital rectal exam and the prostate-specific antigen test and 36 associated laboratory work. "Prostate cancer screening" shall also 37 include subsequent follow up testing as direct by a health care 38 provider, including, but not limited to:

39 (1) urinary analysis;

(2) serum biomarkers;

41 (3) medical imaging, including, but not limited to, magnetic42 resonance imaging.

43

40

10. (New section) a. The School Employees' Health Benefits
Commission shall ensure that every contract purchased by the
commission on or after the effective date of this act that provides
hospital or medical expense benefits shall provide coverage for an
annual prostate cancer screening.

### **S791 SINGLETON**

1 The benefits shall be provided to the same extent as for any other 2 medical condition under the contract except that no deductible, 3 coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed. 4

5 b. As used in this section:

"Prostate cancer screening" means medically viable methods for 6 7 the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and 8 9 associated laboratory work. "Prostate cancer screening" shall also 10 include subsequent follow up testing as direct by a health care 11 provider, including, but not limited to:

12 (1) urinary analysis;

13 (2) serum biomarkers;

14 (3) medical imaging, including, but not limited to, magnetic 15 resonance imaging.

11. This act shall take effect on the 90th day next following the date of enactment and shall apply to all contracts and policies 18 delivered, issued, executed, or renewed on or after that date.

#### **STATEMENT**

24 This bill requires health, hospital, and medical service 25 corporations, health maintenance organizations, and commercial 26 group health insurers to provide coverage for an annual prostate 27 cancer screening without cost sharing. Under current law, these health insurance carriers are required only to provide coverage for 28 29 an annual medically recognized diagnostic examination including, 30 but not limited to, a digital rectal examination and a prostate-31 specific antigen test for men age 50 and over who are asymptomatic and for men age 40 and over with a family history of prostate 32 33 cancer or other prostate cancer risk factors. The bill expands the definition of "prostate cancer screening" to mean medically viable 34 35 methods for the detection and diagnosis of prostate cancer, which 36 includes a digital rectal exam and the prostate-specific antigen test 37 and associated laboratory work. "Prostate cancer screening" shall 38 also include subsequent follow up testing as direct by a physician, 39 including, but not limited to:

- 40 (1) urinary analysis;
- 41 (2) serum biomarkers;

42 (3) medical imaging, including, but not limited to, magnetic 43 resonance imaging.

44 The bill also extends the prostate cancer screening requirements 45 to commercial individual health insurers, health benefits plans 46 issued pursuant to the New Jersey Individual Health Coverage and

17

16

- 19 20
- 21
- 22 23

## **S791** SINGLETON 9

- 1 Small Employer Health Benefits Programs, the State Health
- 2 Benefits Program, and the School Employees' Health Benefits
- 3 Program, which are not required to provide this coverage under
- 4 current law.